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BACKGROUND: The metastatic propensity of invasive ductal carcinoma (IDC) of the breast correlates with axillary node involvement
and with expression of the proliferation antigen Ki-67, whereas ductal carcinoma in situ (DCIS) is non-metastasising. To clarify
whether concomitant DCIS affects IDC prognosis, we compared Ki-67 expression and node status of size-matched IDC subgroups
either with DCIS (IDC-DCIS) or without DCIS (pure IDC).
METHODS: We analysed data from 1355 breast cancer patients. End points were defined by the association of IDC (with or without
DCIS) with grade, nodal status, Ki-67, and ER/HER2.
RESULTS: Size-matched IDC-DCIS was more likely than pure IDC to be screen detected (P¼ 0.03), to occur in pre-menopausal
women (P¼ 0.002), and to be either ER-positive (P¼ 0.002) or HER2-positive (Po0.0005), but less likely to be treated with
breast-conserving surgery (P¼ 0.004). Grade and Ki-67 were lower in IDC-DCIS than in pure IDC (P¼ 0.02), and declined as the
DCIS enlarged (Po0.01). Node involvement and lymphovascular invasion in IDC-DCIS increased with the size ratio of IDC to
DCIS (Po0.01). A 60-month cancer-specific survival favoured IDC-DCIS over size-matched pure IDC (97.4 vs 96.0%).
CONCLUSION: IDC co-existing with DCIS is characterised by lower proliferation and metastatic potential than size-matched pure IDC,
especially if the ratio of DCIS to IDC size is high. We submit that IDC-DCIS is biologically distinct from pure IDC, and propose an
incremental molecular pathogenesis of IDC-DCIS evolution involving an intermediate DCIS precursor that remains dependent for
replication on upstream mitogens.
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Widespread use of breast cancer screening with mammography
has led to a steep rise in the incidence of ductal carcinoma in situ
(DCIS; van Steenbergen et al, 2009), whereas the overall incidence
of invasive ductal carcinoma (IDC) is decreasing (Jemal et al,
2009). Although DCIS is pre-malignant (Pinder and Ellis, 2003),
the modest improvement in breast cancer mortality attributable to
such screening (Mandelblatt et al, 2009; Nelson et al, 2009) has
suggested that many DCIS cases never progress to invasive disease,
raising questions about the contribution of DCIS to the natural
history of sporadic IDC (Allred et al, 2001; Burstein et al, 2004). In
tumours containing both IDC and DCIS (IDC-DCIS), it is unclear
whether the IDC component arises directly from DCIS; in tumours
lacking DCIS, however, it is assumed that IDC arises de novo. One
recent study implicated DCIS as the precursor of IDC-DCIS based
on concordant expression of immunohistochemical markers
(Steinman et al, 2007), a conclusion that has since been supported
by genomic data (Aubele et al, 2000; Alexe et al, 2007; Iakovlev
et al, 2008), in turn creating a quest for biomarkers that predict
invasive transformation of DCIS (Schuetz et al, 2006; Castro et al,
2008). Other studies have reported differences between DCIS
and IDC-DCIS, suggesting that DCIS may not have been a
precursor of the invasive component (Farabegoli et al, 2002);
however, some of these studies have been limited either by failure
to use pure IDC as a comparator (Patla et al, 2002) or else by small
cohort sizes (Mylonas et al, 2005). Yet another study concluded
that the presence of DCIS was associated with a trend towards
superior disease-free survival (DFS) and overall survival, but that it
was not an independent predictor of outcome (Chagpar et al,
2009).
Proliferation antigen Ki-67 (Gerdes et al, 1991) is a biomarker of
tumour activity, and an adverse prognostic factor in patients with
IDC (Fitzgibbons et al, 2000; Jung et al, 2009). Elevated Ki-67
expression may predict progression to cancer in some precursor
lesions (Shaaban et al, 2002); in DCIS, high Ki-67 expression levels
may predict in situ or invasive recurrence (Simpson et al, 2007).
Indeed, together with lymph node status, Ki-67 has been impli-
cated as one of only two factors with an independent prognostic
value for survival (Jung et al, 2009); in tumours not stratified
for DCIS status, Ki-67 expression appears prognostically indepen-
dent of tumour size and nodal status (Barnard et al, 1987;
Bouzubar et al, 1989; Locker et al, 1992). Because presence of DCIS
may bias the detectability of an associated IDC lesion, we chose in
this study to focus on the biological characteristics – Ki-67, nodal
status, and receptor expression – of similarly sized IDC with or
without DCIS.
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PATIENTS AND METHODS
Patients
Tumour data obtained from 2271 consecutive patients undergoing
surgery for primary invasive breast cancer between October 2000
and September 2008 in a single centre were analysed retro-
spectively. Male patients (n¼ 2), patients with histopathological
diagnoses other than ductal carcinoma, such as lobular carcinoma
(n¼ 75), those who had received neoadjuvant chemotherapy
(n¼ 56), those with metastatic disease (n¼ 71) and samples with
incomplete pathological examination or data (n¼ 712) were
excluded.
Tumour morphology
The remaining evaluable samples numbered 1355. They were
divided into three subgroups based on the association of IDC with
DCIS or otherwise, into pure IDC, IDC associated with co-existing
DCIS (IDC-DCIS), and pure DCIS. Within the group of IDC-DCIS,
the samples were further classified into (1) small IDC–large DCIS,
(2) large IDC–small DCIS, and (3) IDC-DCIS with comparable
sizes, based on respective median sizes of IDC (1.8 cm) and DCIS
(1.5 cm) as the cut-off values. The three subgroups were thus
defined to be (1) small IDC (o1.8 cm) large DCIS (X1.5 cm), (2)
large IDC (X1.8 cm) small DCIS (o1.5 cm), and (3) all remaining
IDC-DCIS samples. The IDC to DCIS size ratio for each tumour
sample was also determined. Sizes of DCIS within IDC-DCIS
tumours were initially reported either in terms of largest diameter
(cm/mm) or else as a percentage of IDC size; in the latter group,
DCIS diameters were calculated from the IDC diameters and
rounded to the nearest decimal place. Tumours with DCIS reported
to be o1% IDC size were defined for this study as pure IDC.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffin-
embedded specimens in a reference laboratory by a dedicated
pathologist followed a standard protocol. Immunohistochemistry
for ER and PR was performed using 6F11 and 1A6 antibodies
respectively, and detected by the polymer EnVision system (Dako,
Glostrup, Denmark). ER/PR results were reported with a semi-
quantitative H-score ranging from 0 to 300; a score above 10 was
considered positive. The immunohistochemistry assay used for
HER2 was A0485 (polyclonal antibody; Dako). HER2 was
considered positive with either 3þ immunoreactivity or amplifi-
cation by fluorescent in situ hybridisation (FISH) with a ratio of
HER2 to chromosome 17 centromeric region 42.2, using
PathVysion Vysis FISH (Abbott, Chicago, IL, USA). Expression
of Ki-67 was assessed by immunostaining with antibody SP6, and
was reported as the percentage of positive tumour cells. In cases of
IDC-DCIS, Ki-67 values of the invasive cancer component alone
were used for comparative analyses.
Statistical analysis
The median test was used to calculate statistical differences in
the Ki-67 index between subgroups; if a difference was found,
Spearman’s correlation statistics were used to define the relation-
ship between these co-variables. When comparing IDC-DCIS and
pure IDC, partial correlations were calculated by controlling for
sizes of the invasive cancer component.
Nodal status, lymphovascular invasion, and outcomes
The number of involved nodes, and the presence or absence
of lymphovascular invasion, was determined by routine haema-
toxylin–eosin staining. Patient DFS were ascertained using
Kaplan–Meier methodology.
RESULTS
Patients, demographics, histology, and mode of primary
tumour detection
The median age of the 1355 subjects was 48 years (range 24–91
years). All were women; most (64.3%) were pre-menopausal,
consistent with local epidemiology. Of all tumour samples, 616
(45.5%) were IDC-DCIS; 543 (40.1%) were pure IDC; and the
remaining 196 (14.4%) were pure DCIS. Screening mammography
detected breast lesions in 169 cases (12.5%), whereas 1036 (76.5%)
were self-discovered; 5.7 and 11.5% of patients with IDC and IDC-
DCIS, respectively, were diagnosed by screening mammography,
whereas 34.2% of patients with pure DCIS were diagnosed by
this mode (data not shown). After correcting for IDC size, a partial
correlation coefficient of 0.091 (P¼ 0.003) favoured pure IDC
self-detection and IDC-DCIS screen detection; these data may be
pertinent to future cost-efficacy analyses related to screening.
Breast-conserving surgery was more common in pure IDC than in
IDC-DCIS (47.3 vs 39.0%, P¼ 0.004), however, implying that more
extensive DCIS lesions tended to favour mastectomy despite the
higher frequency of screen detection in this group (Table 1).
Tumour size and proliferation rate
As shown in Table 2, median sizes of IDC and DCIS were 1.8 and
1.5 cm (range 0.01–10.0 and 0.1–10.0 cm) respectively. Median
Ki-67 levels were higher in pure IDC, compared with IDC-DCIS of
comparable invasive size, as determined by the one-tailed median
test (P¼ 0.03). There was also an overall difference between
IDC±DCIS and increasing Ki-67 levels, such that pure IDC was
associated with higher Ki-67 than was IDC-DCIS (Spearman’s
correlation coefficient 0.07, P¼ 0.02). After controlling for the
sizes of the invasive component, the partial correlation coefficient
was still significant at 0.08 (P¼ 0.01). In addition, more patients
with pure IDC had a higher Ki-67 expression (Figure 1). Analyses
on other subgroups were concordant: IDC-DCIS comprised large
IDC (X1.8 cm) with small DCIS (o1.5 cm) correlated with higher
Ki-67 levels than IDC-DCIS with small IDC (o1.8 cm) and large
DCIS (X1.5 cm), which in turn had higher Ki-67 levels than pure
DCIS (correlation coefficient, 0.2; Po0.005). Furthermore,
higher IDC to DCIS size ratio was associated with higher Ki-67
(Pearson’s correlation coefficient, 0.125; P¼ 0.002).
Receptor expression profile
Compared with pure IDC, IDC-DCIS tumours were more often ER
positive (81.5 vs 74.0%, P¼ 0.002), PR positive (74.7 vs 70.5%,
P¼ 0.114), and/or HER2 positive (25.5 vs 16.2%, Po0.0005). These
IDC-DCIS trends were similar in pure DCIS (Table 3), supporting
the view that the IDC-DCIS phenotype reflects that of the
associated (presumably precursor) DCIS. Moreover, as HER2
expression and ER expression tend to be inversely related, this
dual finding suggests a broader dependence of IDC-DCIS on
mitogenic signalling.
Metastasis and survival
Table 4 shows that most patients (66.4%) were free of nodal
involvement; 301 (22.2%) had 1–3 involved lymph nodes, whereas
137 (10.1%) had 4 or more involved nodes. Within the 616
IDC-DCIS samples, the mean value of IDC to DCIS size ratio was
5 (range 0.025–50). There was a trend towards higher number of
involved lymph nodes in pure IDC compared with IDC-DCIS
(Pearson’s correlation coefficient, 0.052; P¼ 0.078). Within the
IDC-DCIS group, higher IDC to DCIS size ratio correlated with
more involved lymph nodes (Pearson’s correlation coefficient,
0.112; P¼ 0.006). Similarly, IDC-DCIS cases with large IDC–small
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DCIS were more often associated with lymphovascular invasion
(57.7%) than were small IDC–large DCIS (27.0%; Po0.0005); this
finding was confirmed by the correlation between higher IDC-
DCIS size ratio with lymphovascular invasion (Spearman’s
correlation coefficient, 0.163, Po0.0005). With a median follow-
up of 29.3 months, the 5-year DFS rates of the IDC-DCIS and pure
IDC subgroups were 97.40 and 96.00% respectively (not signifi-
cant; P¼ 0.38).
DISCUSSION
Breast cancer is a heterogenous disease, and much research has
been directed towards identifying subtypes to aid risk stratifica-
tion. The paradigm of early breast cancer management is thus
shifting towards ‘personalising’ therapy as a function of morpho-
logical, biological, and molecular disease variables (Epstein, 2009).
In situ cancer – especially DCIS – has attracted much interest
Table 2 Tumour size, grade, and Ki-67 expression in patients with pure IDC vs IDC-DCIS
IDC-DCIS
Characteristics All cases Pure IDC All IDC–DCIS Small IDC– large DCIS Large IDC–small DCIS
IDC size (cm)
Median (range) 1.8 (0.01–10.0) 1.8 (0.12–10.0) 1.8 (0.01–8.00) 0.7 (0.01–1.7) 2.5 (1.8–8.0)
p2 50.0 (678) 58.0 ((315) 58.9 (363) 100 (189) 15.8 (35)
42–5 32.6 (442) 37.9 (206) 38.3 (236) 0.0 (0) 79.3 (176)
45 2.9 (39) 4.1 (22) 2.8 (17) 0.0 (0) 5.0 (11)
DCIS size (cm)
Median (range) 1.5 (0.1–10.0) NA 1.0 (0.1–10.0) 3.4 (1.5–10.0) 0.3 (0.1–1.4)
Grade
1 9.4 (128) 8.3 (45) 13.3 (82) 15.3 (29) 12.2 (27)
2 30.9 (419) 35.5 (193) 36.7 (226) 41.6 (77) 32.0 (71)
3 44.1 (598) 54.7 (297) 48.9 (301) 41.8 (79) 55.9 (124)
Unknown 15.5 (210) 1.5 (8) 1.1 (7) 2.1 (4) 0.0 (0)
Ki-67 index (%)
Mean, median 21.3, 13.0 25.3, 15.0 21.0, 14.0 19.1, 12.0 23.5, 15.5
p10 45.7 (619) 40.1 (218) 44.0 (271) 47.6 (90) 36.0 (80)
410–20 21.2 (287) 19.7 (107) 22.7 (140) 22.8 (43) 23.9 (53)
420 33.1 (449) 40.1 (218) 33.3 (205) 29.6 (56) 40.1 (89)
Total number 1355 543 616 189 222
Abbreviations: IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ. Results are presented as percentages, with raw data following in parentheses.
Table 1 Demographic, detection, and surgical data of patients with pure IDC, IDC-DCIS, and pure DCIS
IDC-DCIS
Characteristics All cases Pure IDC All IDC-DCIS Small IDC– large DCIS Large IDC–small DCIS
Age at diagnosis
Median (range) 48 (24–91) 49 (24–91) 47 (26–86) 47 (26–83) 47 (29–86)
p35 7.5 (101) 8.1 (44) 6.7 (41) 7.4 (14) 6.8 (15)
36–50 53.5 (726) 47.5 (258) 58.1 (358) 60.3 (114) 54.5 (121)
X51 38.5 (521) 43.3 (235) 35.2 (217) 32.3 (61) 38.7 (86)
Unknown 0.5 (7) 1.1 (6) 0.0 (0) 0.0 (0) 0.0 (0)
Menopausal status
Pre-menopausal 64.3 (871) 58.6 (318) 67.2 (414) 70.4 (133) 62.6 (139)
Post-menopausal 35.7 (484) 41.4 (225) 32.8 (202) 29.6 (56) 37.4 (83)
Mode of discovery
Mammographic screening 12.5 (169) 5.7 (31) 11.5 (71) 18.5 (35) 4.5 (10)
Self-detected 76.5 (1036) 82.7 (449) 77.4 (477) 68.8 (130) 86.9 (193)
Others 11.1 (150) 11.6 (63) 11.0 (68) 12.7 (24) 8.6 (19)
Primary surgery
Mastectomy and axillary dissection 15.1 (205) 16.0 (87) 18.8 (116) 16.9 (32) 19.4 (43)
Lumpectomy and axillary surgery
(including sentinel lymph node biopsy)
40.3 (546) 47.3 (257) 39.0 (240) 22.8 (43) 47.7 (106)
Lumpectomy alone 1.8 (24) 1.5 (8) 0.5 (3) 0.5 (1) 0.0 (0)
Others 42.8 (580) 35.2 (191) 41.7 (257) 59.8 (113) 32.9 (73)
Total number 1355 543 616 189 222
Abbreviations: IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ. Data are presented as percentages, with numerical results following in parentheses.
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because of its rising incidence in the mammography era, but there
are few studies scrutinising the significance of IDC co-existing with
DCIS (Chagpar et al, 2009). Currently, the association of DCIS in
IDC has no bearing on systemic treatment, which depends entirely
on the pathological and molecular characteristics of IDC. It
therefore remains unclear whether IDC-DCIS behaves identically
to pure IDC or otherwise, notwithstanding that this distinction
could have significant implications for adjuvant treatment in early
breast cancer.
This study reports the largest cohort yet published relating to
this issue, showing that the extent of DCIS with IDC correlates with
lower Ki-67 index and fewer involved lymph nodes. Although the
pre-malignant DCIS may well have permitted earlier detection
Table 3 Comparative receptor expression profile – ER/PR and HER2
protein immunohistochemical status – of pure IDC, IDC-DCIS, and pure
DCIS
Receptor phenotype Pure IDC IDC-DCIS Pure DCIS
ER-negative 26.0 (141) 18.5 (114) 22.4 (44)
ER-positive 74.0 (402) 81.5 (502) 77.6 (152)
PR-negative 29.5 (160) 25.3 (156) 25.0 (49)
PR-positive 70.5 (383) 74.7 (460) 75.0 (147)
HER2-negative 82.9 (450) 73.2 (451) 65.3 (128)
HER2-positive 16.2 (88) 25.5 (157) 34.7 (68)
Abbreviations: ER¼ oestrogen receptor; PR¼ progesterone receptor;
IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ. Results are
presented as percentages, with numerical case data following in parentheses.
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Figure 1 Percentage of invasive ductal carcinoma (IDC) with and
without ductal carcinoma in situ (DCIS) with different Ki-67 levels. The
higher the Ki-67 level, the larger the proportion of pure IDC, and vice versa
for IDC-DCIS. Black bars, pure IDC; white bars, IDC-DCIS.
Table 4 Nodal status and lymphovascular invasion in pure IDC vs IDC-DCIS
IDC-DCIS
Characteristics All cases Pure IDC All IDC–DCIS Small IDC– large DCIS Large IDC–small DCIS
Lymph node status
Negative 66.4 (900) 58.9 (320) 62.3 (384) 72.0 (136) 55.4 (123)
1–3 lymph nodes 22.2 (301) 26.7 (145) 25.3 (156) 17.5 (33) 29.7 (66)
4–9 lymph nodes 6.9 (94) 8.7 (47) 7.6 (47) 6.3 (12) 10.8 (24)
49 lymph nodes 3.2 (43) 5.0 (27) 2.6 (16) 1.1 (2) 3.6 (8)
Unknown 1.3 (17) 0.7 (4) 2.1 (13) 3.2 (6) 0.5 (1)
Lymphovascular invasion
Negative 65.2 (884) 60.8 (330) 58.3 (359) 73.0 (138) 42.3 (94)
Positive 34.8 (471) 39.2 (213) 41.7 (257) 27.0 (51) 57.7 (128)
Total number 1355 543 616 189 222
Abbreviations: IDC¼ invasive ductal carcinoma; DCIS¼ ductal carcinoma in situ. Data are presented as percentages, with total case numbers following in parentheses.
Normal breast
ductal epithelium
Minor mutation/
methylation event(s)
Minor mutation/
methylation event(s)
DCIS
IDC-DCIS Pure IDC
Major gene
mutation event(s)
Figure 2 Hypothetical carcinogenesis model for invasive ductal
carcinoma–ductal carcinoma in situ (IDC-DCIS) vs pure IDC. In this
model, IDC-DCIS – intrinsically less aggressive as reflected by lower Ki-67
expression and less nodal involvement – develops stepwise from normal
breast epithelium via DCIS, through acquiring minor sequential genetic
dysfunctions each time, whereas pure IDC develops de novo due to major
genetic event(s).
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of the IDC component than would otherwise occur for a pure IDC
of similar size, the fact that the proliferative and metastatic
differences persist after controlling for IDC size supports the
impression of a biological difference between IDC-DCIS and
pure IDC. This conclusion is further supported by the finding
of increased ER/PR and/or HER2 expression in IDC-DCIS,
suggesting in turn that the pure IDC carcinogenesis pathway
could favour the therapeutically challenging basaloid phenotype,
which is already known to be associated with multiple defects
in tumour suppressor genes such as TP53 and the BRCA DNA
repair genes.
These results imply that IDC-DCIS tends to have lower disease
aggressiveness than pure IDC, particularly as DCIS-IDC size ratios
increase. Such a model is reminiscent of colorectal cancer that may
arise either through a polyp-dependent (adenoma carcinoma)
process, or through a non-polyp-dependent (de novo) pathway
associated with greater invasive and metastatic potential (Tanaka,
2009). In preclinical models of breast cancer, disruption of the
TP53 pathway and/or constitutive activation of HER2, FAK or
KRAS produce DCIS, but further inhibition of pRb signalling and/
or activation of the phosphatidylinositol 30-kinase pathway appear
necessary to promote malignant progression (Lightfoot et al, 2004;
Golubovskaya et al, 2009; Wu et al, 2009). Comparative genomic
hybridisation studies have also identified genetic pathways – for
example through loss of genetic material of 16q associated with
well-differentiated to intermediately differentiated DCIS and grade
1 IDC, or gains of 8q, 17q, and 20q associated with poorly
differentiated DCIS and grade 3 IDC (Buerger et al, 2001) – that
support a linear progression model for the transition from normal
to DCIS to IDC. However, the heterogeneity of genetic changes in
DCIS compared to IDC suggests other breast cancer progression
pathways (Gao et al, 2009). Hence, given that fast-replicating (high
Ki-67) tumours might be expected to contain a higher burden of
dysfunctional tumour suppressor genes, our study results raise the
possibility that pure IDC tumours arise as a result of more drastic
tumour suppressor gene defects, whereas IDC-DCIS tumours tend
to evolve as a result of a more incremental accumulation of milder
suppressor gene defects (Figure 2).
We acknowledge that this study has several important limita-
tions. First, it is a retrospective analysis, from which almost one-
third of case records originally examined were excluded due to
incomplete data. Second, there were variations in pathology
reporting styles, as the tumour samples were not centrally
reviewed. Third, the median follow-up time of 30 months is too
short to expect major differences in disease-free survival to have
emerged. Fourth, it must remain speculative for now whether
concomitant DCIS will emerge as a useful independent prognostic
variable, as the degree of biological overlap between size-matched
IDC-DCIS and pure IDC may preclude this. Finally, we acknowl-
edge that the postulation of molecular differences between
IDC-DCIS and pure IDC, as posited in Figure 2, remains entirely
speculative at this point, and that any such assumption is
premature. We hope, however, that the indirect clinicopathological
observations provided here might provoke more specific genetic
and scientific hypothesis testing in this clinical context.
In conclusion, this study raises the possibility that the
association or otherwise of IDC with a DCIS precursor, and the
relative sizes of these two lesions, could be factored into future
adjuvant therapeutic decision-making. If verified, this distinction
would in turn suggest an as-yet-undetermined molecular basis for
the divergent clinical behaviour of these breast lesion subtypes.
Future work is needed to test the observations noted here, and to
explore molecular explanations for the putative differences in
natural history.
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